Stocks and Investing Stocks and Investing
Mon, May 9, 2022
Fri, May 6, 2022

Mohit Bansal Maintained (VRTX) at Buy with Increased Target to $305 on, May 6th, 2022


Published on 2024-10-27 20:55:02 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $300 to $305 on, May 6th, 2022.

Mohit has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022


These are the ratings of the 6 analyists that currently disagree with Mohit


  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $291 on, Thursday, May 5th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 3rd, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
Contributing Sources